Source comparison
CJC-1295 no DAC & Ipamorelin 60s Age Specific Protocol: Comparison
Dosing Frequency Once daily (typically bedtime) Twice daily (morning + bedtime) Ageing pituitary responsiveness diminishes. Splitting doses maintains pulse frequency without requiring higher per-dose amounts CJC-1295 Dose 200–300mcg per administration 100–200m
This comparison does not assign a generated winner or score.
- Dosing Frequency
- Once daily (typically bedtime)
- Twice daily (morning + bedtime)
- Ageing pituitary responsiveness diminishes. Splitting doses maintains pulse frequency without requiring higher per-dose amounts
- CJC-1295 Dose
- 200–300mcg per administration
- 100–200mcg per administration
- Lower per-dose amount prevents IGF-1 overshooting in metabolically sensitive populations while maintaining pulse amplitude
- Ipamorelin Dose
- Ghrelin receptor sensitivity is preserved in older adults. Lower doses achieve equivalent amplification with reduced desensitization risk
- Titration Timeline
- Increase dose every 2–3 weeks if needed
- Hold starting dose for 8 weeks, then assess IGF-1 before adjusting
- Slower metabolic turnover in 60+ populations means peak response appears later. Premature titration overshoots target
- IGF-1 Target Range
- Upper half of reference range for age
- Upper quartile of age-matched range (not youthful range)
- Targeting youthful IGF-1 in older adults increases insulin resistance and cancer proliferation risk
- Cycle Duration
- 12–16 weeks on, 4 weeks off
- 16–20 weeks on, 4–6 weeks off
- Longer cycles are better tolerated in 60+ populations due to slower receptor downregulation. Extended off-periods allow full pituitary recovery